Celgene, Natco Pharma Ltd. cancer news

Celgene disclosed in its 3Q10 earnings that it filed suit in October in the U.S. District Court for the District of New Jersey alleging that an ANDA filed by Natco for a generic version of Celgene's Revlimid lenalidomide infringes 10 U.S. patents. The ANDA, which was filed in August, contains a paragraph IV certification that the patents, which expire between 2016 and 2026, are invalid, unenforceable or not infringed. In addition, Celgene claimed that Natco has a New Jersey partner. Natco refused to identify the partner, but did not deny that the partner exists. Celgene is seeking to prevent the approval and sale of the generic before the patents expire (see BioCentury, Aug. 30). ...